Carmell Corporation Secures Pipeline Investment to Fuel Growth
PITTSBURGH — Carmell Corporation (NASDAQ: CTCX), a prominent bio-aesthetics company dedicated to enhancing skin and hair health, has revealed a new round of investment aimed at supporting its commercial expansion.
Details of the Investment
Carmell has entered into a securities purchase agreement with both new and existing investors. This agreement includes the issuance and sale of 8,065,210 shares of common stock along with equivalent warrants, all priced at $0.23 per share. The private placement is expected to generate approximately $1.85 million before accounting for offering expenses and fees.
Mr. Rajiv Shukla, Chairman of Carmell, expressed enthusiasm about this investment, stating, “We are pleased to announce this additional round of funding. It will significantly bolster our efforts to expand our revolutionary bio-aesthetics product pipeline.”
Future Projections and Impact
Upon completion of this private placement, Carmell's outstanding shares of common stock will total around 29 million. Investors will have the option to exercise their warrants starting the trading day after the Stockholder Approval Date, providing potential for an extra $1.85 million in proceeds for the company. The closing of this private placement is contingent on customary closing conditions.
Brookline Capital Markets, a division of Arcadia Securities, LLC, has taken on the role of exclusive placement agent for this transaction.
Understanding Carmell's Innovative Approach
Carmell is at the forefront of bio-aesthetics innovation with its flagship product, the Carmell Secretome™. This proprietary formulation harnesses a blend of growth factors and proteins derived from allogeneic human platelets that are sourced from FDA-approved tissue banks.
Commitment to Skin and Hair Health
The Carmell Secretome™ has undergone extensive evaluation over the past seven years, ensuring it meets the highest standards of efficacy and safety. Moreover, the company has pioneered a unique microemulsion delivery system that allows for the inclusion of both lipophilic and hydrophilic ingredients without relying on harmful excipients typical in the cosmetics industry. This approach not only elevates product performance but also prioritizes the health of the skin.
Expanding Product Lines
Carmell’s innovative products are tailored to satisfy the rigorous standards set by both professional care providers and discerning retail customers. The company's upcoming launches include specialized men's products and topical solutions for haircare, demonstrating its commitment to addressing a diverse range of consumer needs.
Regulatory Considerations and Future Endeavors
It is important to note that the shares involved in this private placement have not been registered under the Securities Act of 1933 and cannot be offered in the United States without the appropriate exemptions or registrations. Carmell plans to file a registration statement with the SEC to facilitate the resale of stocks acquired through this placement.
Investor Relations and Contact
For more inquiries, investors can reach out to Bryan J. Cassaday via email at bc@carmellcorp.com.
Frequently Asked Questions
What is the purpose of the new PIPE investment by Carmell Corporation?
The PIPE investment aims to support the ongoing commercial build-out of Carmell's innovative bio-aesthetics product pipeline.
How much capital is Carmell Corporation raising with this investment?
Carmell Corporation is raising approximately $1.85 million before expenses through the sale of 8,065,210 shares and warrants.
What products does Carmell offer?
Carmell specializes in bio-aesthetics products, including the Carmell Secretome™, with future offerings for men’s skincare and topical haircare solutions.
Who is the placement agent for this investment?
Brookline Capital Markets, part of Arcadia Securities, LLC, has been appointed as the exclusive placement agent for this private placement.
Will the investments affect the number of shares outstanding for Carmell?
Yes, following the closing of the private placement, Carmell is projected to have around 29 million shares of common stock outstanding.
